Page last updated: 2024-10-27

gaboxadol and Multiple Sclerosis

gaboxadol has been researched along with Multiple Sclerosis in 1 studies

gaboxadol: GABA agonist; inhibitor of GABA uptake systems; structure

Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mondrup, K1
Pedersen, E1

Other Studies

1 other study available for gaboxadol and Multiple Sclerosis

ArticleYear
The acute effect of the GABA-agonist, THIP, on proprioceptive and flexor reflexes in spastic patients.
    Acta neurologica Scandinavica, 1983, Volume: 67, Issue:1

    Topics: Adult; Female; Humans; Isoxazoles; Male; Mechanoreceptors; Middle Aged; Multiple Sclerosis; Muscle S

1983